• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's After-Market Session

    10/19/23 5:31:47 PM ET
    $AMTI
    $AMWL
    $ARQT
    $BCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate
    Real Estate
    Get the next $AMTI alert in real time by email

    Gainers

    • American Well (NYSE:AMWL) stock moved upwards by 22.9% to $1.16 during Thursday's after-market session. American Well's trading volume hit 1.3 million shares by close, accounting for 101.4% of its average volume over the last 100 days. The company's market cap stands at $330.2 million.
    • Comera Life Sciences (NASDAQ:CMRA) stock rose 12.73% to $0.3. The market value of their outstanding shares is at $9.2 million.
    • Generation Bio (NASDAQ:GBIO) stock rose 10.83% to $1.33. Trading volume for this security closed at 62.0K, accounting for 38.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $87.6 million.
    • Applied Molecular (NASDAQ:AMTI) stock moved upwards by 10.23% to $0.16. Trading volume for this security closed at 377.8K, accounting for 35.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.4 million.
    • HOOKIPA Pharma (NASDAQ:HOOK) stock moved upwards by 9.99% to $0.53. The market value of their outstanding shares is at $44.7 million.
    • GRI Bio (NASDAQ:GRI) shares rose 9.0% to $1.33. The market value of their outstanding shares is at $3.9 million.

    Losers

    • Atreca (NASDAQ:BCEL) shares fell 15.8% to $0.31 during Thursday's after-market session. This security traded at a volume of 3.6 million shares come close, making up 253.7% of its average volume over the last 100 days. The market value of their outstanding shares is at $12.1 million.
    • Processa Pharma (NASDAQ:PCSA) shares fell 13.01% to $0.47. At the close, Processa Pharma's trading volume reached 1.2 million shares. This is 72.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $11.5 million.
    • Ontrak (NASDAQ:OTRKP) stock declined by 9.65% to $0.33.
    • Bio-Path Hldgs (NASDAQ:BPTH) stock fell 9.49% to $0.46. The company's market cap stands at $5.2 million.
    • Arcutis Biotherapeutics (NASDAQ:ARQT) shares fell 8.59% to $2.77. Today's trading volume for this security ended up closing at 138.0K shares, which is 12.2 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $170.7 million.
    • Intuitive Surgical (NASDAQ:ISRG) stock fell 7.67% to $252.49. Today's trading volume for this security ended up closing at 516.5K shares, which is 27.9 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $88.7 billion. As per the press release, Q3 earnings came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMTI
    $AMWL
    $ARQT
    $BCEL

    CompanyDatePrice TargetRatingAnalyst
    Intuitive Surgical Inc.
    $ISRG
    3/11/2026$590.00Neutral → Buy
    Citigroup
    Intuitive Surgical Inc.
    $ISRG
    1/27/2026$660.00Buy
    TD Cowen
    Generation Bio Co.
    $GBIO
    12/16/2025$5.50Neutral → Outperform
    Wedbush
    Generation Bio Co.
    $GBIO
    12/16/2025$5.00Buy → Hold
    Jefferies
    Intuitive Surgical Inc.
    $ISRG
    12/11/2025$635.00Buy → Neutral
    Citigroup
    Generation Bio Co.
    $GBIO
    8/13/2025$7.00Outperform → Neutral
    Wedbush
    Arcutis Biotherapeutics Inc.
    $ARQT
    7/25/2025$18.00Neutral
    Goldman
    Intuitive Surgical Inc.
    $ISRG
    7/23/2025Buy → Hold
    Erste Group
    More analyst ratings

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting

    Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream improved signs and symptoms of mild to moderate atopic dermatitis in infants aged 3 months to less than 24 months over four weeksCaregivers reported rapid improvement in itch in as little as 10 minutes in nearly half of infantsResults from additional studies across the ZORYVE portfolio being presented in three poster presentations WESTLAKE VILLAGE, Calif. and DENVER, March 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaning

    3/28/26 11:00:00 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

    NEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the completion of the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. ("NeoTrail"). The purchase price remains undisclosed. The asset purchase agreement was signed on January 28, 2026, and the closing of the transaction occurred on March 20, 2026. About HB-200 Eseba-vec (also known as HB-200) is an investigational immunotherapeutic agent being evaluated for HPV16 positive cancers. HB-200 alternates the administration of both HB-201 (LCMV) and HB-202 (PIC

    3/26/26 7:00:00 AM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems

    SAN CARLOS, Calif., March 24, 2026 /PRNewswire/ -- Sonder Capital, a healthcare venture capital firm investing in companies revolutionizing the standard of care, today announced the closing of its second fund, Futures II. The fund includes participation from Mayo Clinic and Sutter Health, reflecting their collective interest in innovative technologies that have the potential to advance the future of patient care by enhancing access, improving quality and transforming the overall patient experience."Through our second fund we'll continue enabling the next wave of companies and he

    3/24/26 11:03:00 AM ET
    $ISRG
    $PRCT
    $SWAV
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Intuitive Surgical Inc.

    SCHEDULE 13G/A - INTUITIVE SURGICAL INC (0001035267) (Subject)

    3/27/26 9:55:20 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Arcutis Biotherapeutics Inc.

    SCHEDULE 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    3/26/26 11:13:25 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 1-A filed by Bio-Path Holdings Inc.

    1-A - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    3/25/26 2:24:02 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Heron Patrick J bought $34,610 worth of shares (2,646 units at $13.08) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/17/25 5:45:01 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $30,247 worth of shares (2,268 units at $13.34) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    6/6/25 8:44:37 AM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Patrick J bought $68,821 worth of shares (5,040 units at $13.65) (SEC Form 4)

    4 - Arcutis Biotherapeutics, Inc. (0001787306) (Issuer)

    5/23/25 4:04:50 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form

    12/19/23 3:40:08 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ZORYVE issued to ARCUTIS BIOTHERAPEUTICS INC

    Submission status for ARCUTIS BIOTHERAPEUTICS INC's drug ZORYVE (ORIG-1) with active ingredient ROFLUMILAST has changed to 'Approval' on 12/15/2023. Application Category: NDA, Application Number: 217242, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    12/15/23 5:01:31 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Intuitive Surgical upgraded by Citigroup with a new price target

    Citigroup upgraded Intuitive Surgical from Neutral to Buy and set a new price target of $590.00

    3/11/26 8:28:54 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    TD Cowen initiated coverage on Intuitive Surgical with a new price target

    TD Cowen initiated coverage of Intuitive Surgical with a rating of Buy and set a new price target of $660.00

    1/27/26 8:46:58 AM ET
    $ISRG
    Industrial Specialties
    Health Care

    Generation Bio upgraded by Wedbush with a new price target

    Wedbush upgraded Generation Bio from Neutral to Outperform and set a new price target of $5.50

    12/16/25 12:29:16 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Medical Officer Curet Myriam exercised 105 shares at a strike of $229.39 and sold $51,865 worth of shares (105 units at $493.95) (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    3/11/26 1:46:06 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    SVP & Chief Mfg and Supply Cha Brosius Mark sold $630,475 worth of shares (1,293 units at $487.61), decreasing direct ownership by 44% to 1,613 units (SEC Form 4)

    4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

    3/10/26 2:24:12 PM ET
    $ISRG
    Industrial Specialties
    Health Care

    Chief Financial Officer Hirschhorn Mark was granted 50,413 shares, increasing direct ownership by 25% to 253,999 units (SEC Form 4)

    4 - American Well Corp (0001393584) (Issuer)

    3/6/26 5:00:35 PM ET
    $AMWL
    Real Estate

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    Financials

    Live finance-specific insights

    View All

    Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026Announced expansion of its dermatology sales force and, separately, the initiation of a targeted Arcutis commercialization effort for primary care and pediatric health care providersProduced positive op

    2/25/26 4:00:00 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amwell® Announces Results for Fourth Quarter and Full Year 2025

    BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced financial results for the fourth quarter and full year ended December 31, 2025. The company's fourth quarter and full year 2025 earnings report can be viewed at investors.amwell.com. Amwell will host a conference call to discuss its financial results today at 5 p.m. ET. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/7o2zjx2o/. A webcast replay will be available for approximately 90 days at investors.amwell.com. About Amwell Amwell offers payers and health systems a si

    2/12/26 4:05:00 PM ET
    $AMWL
    Real Estate

    Amwell® to report fourth quarter and full year 2025 operating results

    BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at

    2/5/26 4:05:00 PM ET
    $AMWL
    Real Estate

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    Leadership Updates

    Live Leadership Updates

    View All

    NodThera Appoints Geoff McDonough, M.D., as Chief Executive Officer

    Dr. McDonough brings global company-building, commercial strategy, and R&D leadership experience to the Company ahead of key clinical milestones NodThera plans to report results from two Phase 2 cardiometabolic trials RESOLVE-1 and RESOLVE-2 in mid-2026 and third quarter 2026 respectively Company preparing to begin cardiometabolic Phase 3 trial in 1H 2027 BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address unmet needs in cardiometabolic and neuroinflammatory diseases driven by the NLRP3/IL-6/IL-1 inflammation pathway, announced the appointment o

    2/4/26 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NodThera Appoints Geoff McDonough, M.D., as Independent Board Member

    BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- NodThera, a clinical-stage biotechnology company pioneering a paradigm shift in the treatment of chronic inflammatory diseases through selective NLRP3 inhibition, today announced the appointment of Geoff McDonough, M.D., as an Independent Board Member. Dr. McDonough brings more than two decades of leadership experience spanning R&D, commercial strategy, and global company building. He most recently served as President and Chief Executive Officer of Generation Bio (NASDAQ:GBIO). Dr. McDonough previously served as President and CEO of Sobi, overseeing substantial portfolio expansion and international growth. Earlier in his career, Dr. McDonough spen

    12/16/25 8:00:00 AM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMTI
    $AMWL
    $ARQT
    $BCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

    SC 13G/A - Generation Bio Co. (0001733294) (Subject)

    12/9/24 6:18:02 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Arcutis Biotherapeutics Inc.

    SC 13G/A - Arcutis Biotherapeutics, Inc. (0001787306) (Subject)

    11/14/24 7:50:59 PM ET
    $ARQT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by HOOKIPA Pharma Inc.

    SC 13G/A - HOOKIPA Pharma Inc. (0001760542) (Subject)

    11/14/24 6:07:08 PM ET
    $HOOK
    Biotechnology: Pharmaceutical Preparations
    Health Care